Trial Profile
A Pilot Study of the Safety and Efficacy of SEP-226330 in Subjects with Restless Legs Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2011
Price :
$35
*
At a glance
- Drugs SEP 226330 (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- 14 Jun 2011 New trial record